View : 17 Download: 9

Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes

Title
Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes
Authors
Kang Y.A.Shim T.S.Koh W.-J.Lee S.H.Lee C.-H.Choi J.C.Lee J.H.Jang S.H.Yoo K.H.Jung K.H.Kim K.U.Choi S.B.Ryu Y.J.Kim K.C.Um S.Kwon Y.-S.Kim Y.H.Choi W.-I.Jeon K.Hwang Y.I.Kim S.J.Lee H.-K.Heo E.Yim J.-J.
Ewha Authors
류연주
SCOPUS Author ID
류연주scopus
Issue Date
2016
Journal Title
Annals of the American Thoracic Society
ISSN
2325-6621JCR Link
Citation
vol. 13, no. 3, pp. 364 - 370
Keywords
FluoroquinolonesLevofloxacinMoxifloxacinMultidrug-resistant tuberculosis
Publisher
American Thoracic Society
Indexed
SCOPUS scopus
Abstract
Rationale: We previously showed that the choice of levofloxacin or moxifloxacin for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-TB) did not affect sputumculture conversion at 3 months of treatment. Objectives: To compare final treatment outcomes between patients with MDR-TB randomized to levofloxacin or moxifloxacin. Methods: A total of 151 participants with MDR-TB who were included for the final analysis in our previous trial were followed through the end of treatment. Treatment outcomes were compared between 77 patients in the levofloxacin group and 74 in the moxifloxacin group, based on the 2008 World Health Organization definitions as well as 2013 revised definitions of treatment outcomes. In addition, the time to culture conversion was compared between the two groups. Measurements and Main Results: Treatment outcomes were not different between the two groups, based on 2008 World Health Organization definitions as well as 2013 definitions. With 2008 definitions, cure was achieved in 54 patients (70.1%) in the levofloxacin group and 54 (73.0%) in the moxifloxacin group (P = 0.72). Treatment success rates, including cure and treatment completed, were not different between the two groups (87.0 vs. 81.1%, P = 0.38). With 2013 definitions, cure rates (83.1 vs. 78.4%, P = 0.54) and treatment success rates (84.4 vs. 79.7%, P = 0.53) were also similar between the levofloxacin and moxifloxacin groups. Time to culture conversion was also not different between the two groups (27.0 vs. 45.0 d, P = 0.11 on liquid media; 17.0 vs. 42.0 d, P = 0.14 on solid media). Patients in the levofloxacin group had more adverse events than those in the moxifloxacin group (79.2 vs. 63.5%, P = 0.03), especially musculoskeletal ones (37.7 vs. 14.9%, P = 0.001). Conclusions: The choice of levofloxacin or moxifloxacin made no difference to the final treatment outcome among patients with fluoroquinolone-sensitiveMDR-TB. Copyright © 2016 by the American Thoracic Society.
DOI
10.1513/AnnalsATS.201510-690BC
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
choice.pdf(527.92 kB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE